Cell Signaling of Cancer Therapy
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 418
Special Issue Editors
Interests: cell signaling pathways; cancer therapy; combination treatments; targeted therapeutics; drug delivery systems; preclinical in vivo models; rodents and zebrafish xenograft models; drug-drug interactions; translational oncology
Interests: cell signaling pathways; cancer therapy; combination treatments; targeted therapeutics; histone deacetylase inhibitors; translational oncology; breast cancer; preclinical in vitro models
Special Issue Information
Dear Colleagues,
Since the identification of oncogenic signaling pathways and growth factor-driven networks in the late twentieth century, our understanding of cell signaling in cancer has advanced remarkably. Cell signaling is now recognized as a central determinant of tumor initiation, progression, therapeutic response and resistance. Rather than acting as linear and isolated cascades, signaling pathways in cancer operate as highly dynamic, interconnected networks that adapt to genetic alterations, microenvironmental cues and therapeutic pressure.
Dysregulated signal transduction governs virtually all hallmarks of cancer, influencing proliferation, survival, metabolic reprogramming, immune evasion and cellular plasticity. Importantly, therapeutic interventions, including targeted therapies, immunotherapies and emerging gene-based approaches, exert their effects by modulating these signaling networks, often triggering compensatory or adaptive signaling responses that limit long-term efficacy. Consequently, understanding how cancer therapies reshape intracellular and intercellular signaling has become essential for the development of durable and personalized treatment strategies.
This Special Issue, Cell Signaling of Cancer Therapy, offers an Open Access forum aimed at bringing together original research and review articles addressing the expanding field of cell signaling in cancer therapy. We welcome contributions covering signaling pathway regulation, therapy-induced signaling adaptation, mechanisms of drug resistance, and crosstalk between cancer cells and the tumor microenvironment. Studies exploring gene therapy, RNA-based interventions and genome-editing strategies that target or reprogram oncogenic signaling networks are particularly encouraged. We hope to provide a stimulating resource for researchers investigating how signaling biology can be harnessed to improve cancer treatment outcomes.
Dr. Anna Boguszewska-Czubara
Dr. Anna Wawruszak
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cell signaling
- cancer therapy
- signal transduction
- targeted therapy
- gene therapy
- RNA-based therapeutics
- drug resistance
- tumor microenvironment
- precision oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
